Damage to lung tissue or complete loss of function for patients experiencing infection with a respiratory virus or pathogen is an unfortunate reality for too many. Although many respiratory viruses or bacterial infections can result in lung damage, this topic has been of utmost concern recently due to the adverse effects of the current SARSCoV2 outbreak.
Now more than ever we are in dire need of rapidly progressing effective immunomodulators, antivirals, and therapies that help drive tissue repair to market to alleviate current and future negative outcomes for patients. View this webinar to gain key insights and learn how to analyze and select the appropriate pathogen model to develop your drug program.
Rhiannon Jenkinson, PhD
Director of Science, Discovery Services
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.